The Health Sciences Authority (HSA) in Singapore has approved the application by Pfizer to introduce the branded version of its COVID-19 vaccine, Comirnaty, under the Pandemic Special Access Route.

The Comirnaty COVID-19 Vaccine is manufactured according to the same processes as the Pfizer-BioNTech COVID-19 Vaccine, with the same efficacy and safety aspects. The only difference is the labelled name.

Singapore had received several batches of Comirnaty and the vaccines have been used in its national vaccination programme.

In addition, HSA approved the application by Moderna to introduce the brand name “Spikevax” for its COVID-19 vaccine currently authorised under the Pandemic Special Access Route. There are no changes to the vaccine and its quality, safety and efficacy.